Thieler Law Corp advises investors with losses exceeding $100,000 of the June 18, 2021.lead plaintiff deadline in a class action lawsuit filed against Ocugen, Inc. (NASDAQ: OCGN) (Ocugen, Inc. or “the Company”). The suit is pending in the U.S. District Court for the Eastern District of Pennsylvania and investors, who purchased Ocugen, Inc.  securities between February 2, 2021 and June 10, 2021 (“Class Period”), have until  August 17, 2021. to move for lead plaintiff. You do not need to move for lead plaintiff to be a member of the Class.

If you purchased Ocugen, Inc.  securities during the Class Period, and have losses over $100,000, you may contact Thieler Law Corp by calling at (619) 377 - 4324 or emailing mail@thielerlaw.com . No class has been certified in this case, and if your losses are less than $100,000 you are still a member of the class.

Ocugen, Inc identifies itself as a biopharmaceutical company focused on developing gene therapies to cure blindness and developing a vaccine to save lives from COVID-19. The company’s main developments are a modifier gene therapy platform based on nuclear hormone receptors (“NHRs”) to generate therapies for patient with inherited retinal diseases (“IRDs”) and dry age-related macular degeneration (“AMD”).

On February 5, 2021, after the market close, Ocugen filed a Form 8-K with the SEC. Attached to the Form 8-K as exhibit 99.1 was an investor presentation regarding the Company’s apparent new mission to “develop a vaccine to save lives from COVID19”. The presentation described in great detail the Covaxin vaccine characteristics, the “unmet need in the United States” and Ocugen’s plan to develop and file an Emergency Use Authorization (“EUA”) with the U.S. Food and Drug Administration (“FDA”).

According to the lawsuit, defendants throughout the Class Period made false and/or misleading statements and/or failed to disclose that: (1) the information submitted to the U.S. Food and Drug Administration ("FDA") for the development of a COVID-19 vaccine candidate was insufficient to support an Emergency Use Authorization ("EUA"); (2) Ocugen would not file an EUA with the FDA; and (3) as a result of the foregoing, Ocugen’s financial statements, as well as defendants' statements about Ocugen's business, operations, and prospects, were false and misleading and/or lacked a reasonable basis. When the true details entered the market, the lawsuit claims that investors suffered damages.